Manitoba 8th Province to Approve Revlimid® Funding for Myeloma Patients 16/08/2010
Thalidomide Receives Notice of Compliance from Health Canada 12/08/2010 Canada ranks near the bottom in usage of newer cancer drugs 05/08/2010
John F. Lemieux, President of Myeloma Canada, Interview March 1st, 2010 on CBC Radio’s “Daybreak” program. 01/03/2010
Myeloma Canada Decries Quebec Government’s Limited Approval Of Revlimid® As Third-Line Therapy 24/02/2010
Advocacy program for Revlimid launches in Manitoba and New Brunswick - see drug coverage and access tab on the home page 20/02/2010
Myeloma Canada Applauds Decision by Alberta and Saskatchewan to Fund Revlimid® 05/10/2009
Ontarians with Rare Cancer Offered New Hope - Revlimid to be covered by Ontario Public Drug Programs 04/08/2009 Æterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 03/08/2009 Myeloma Canada Applauds Ontario Government’s Decision to Fund Revlimid 24/07/2009 Quebec approves Velcade As First-Line Treatment For Newly-diagnosed Blood Cancer Patients 11/06/2009
Ontario Government Announces Reimbursement of Velcade as First-Line Treatment for Newly-Diagnosed Patients 13/05/2009
Nova Scotia Says No to Revlimid Funding 14/01/2009
New Oral Therapy for Blood Cancer Approved in Canada 06/10/2008
Velcade for multiple myeloma receives front-line approval in Canada 08/09/2008
Ottawa Moves to Reduce Price of Drug after Cancer Patients Complain of Gouging 31/01/2008
New Approach to Reviewing Cancer Drugs Starts March 1, 2007 28/02/2007
Get the PDF version of the myeloma handbook by clicking here...
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors:
Ortho Biotech Celgene The Binding Site Amgen
